With the increasing power of CRISPR gene editing technology, scientists are on the cusp of offering personalized medicine that corrects or modifies genes to treat or prevent diseases.  However, gene editing carries inherent risks of unintended consequences and off-target effects.  Furthermore, editing the germline (reproductive cells) could have permanent implications for future generations.

• How can we balance the potential benefits of personalized gene editing for treating and preventing diseases with the ethical considerations and potential risks of unintended consequences and off-target effects?
• Should germline editing be permitted, and if so, under what strict guidelines and with what level of oversight?
• How can we ensure equitable access to this potentially life-saving technology, considering the high costs and potential for commercialization?